DK1539231T3 - Iscom-præparation og anvendelse deraf - Google Patents
Iscom-præparation og anvendelse derafInfo
- Publication number
- DK1539231T3 DK1539231T3 DK03738849T DK03738849T DK1539231T3 DK 1539231 T3 DK1539231 T3 DK 1539231T3 DK 03738849 T DK03738849 T DK 03738849T DK 03738849 T DK03738849 T DK 03738849T DK 1539231 T3 DK1539231 T3 DK 1539231T3
- Authority
- DK
- Denmark
- Prior art keywords
- iscom
- complexes
- complex
- mixture
- parts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202110A SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Iscom preparation and use thereof |
PCT/SE2003/001180 WO2004004762A1 (en) | 2002-07-05 | 2003-07-07 | Iscom preparation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1539231T3 true DK1539231T3 (da) | 2009-09-14 |
Family
ID=20288449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03738849T DK1539231T3 (da) | 2002-07-05 | 2003-07-07 | Iscom-præparation og anvendelse deraf |
Country Status (14)
Country | Link |
---|---|
US (3) | US20060121065A1 (pt) |
EP (1) | EP1539231B1 (pt) |
JP (1) | JP4636877B2 (pt) |
AT (1) | ATE434443T1 (pt) |
AU (1) | AU2003245220B2 (pt) |
BR (1) | BRPI0312472B8 (pt) |
CA (1) | CA2491457C (pt) |
DE (1) | DE60328108D1 (pt) |
DK (1) | DK1539231T3 (pt) |
ES (1) | ES2328474T3 (pt) |
NZ (1) | NZ537661A (pt) |
SE (1) | SE0202110D0 (pt) |
WO (1) | WO2004004762A1 (pt) |
ZA (1) | ZA200500073B (pt) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) * | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2592627C (en) * | 2005-01-20 | 2014-02-25 | Isconova Ab | Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide |
EP1764369A1 (de) * | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
CN101448523A (zh) | 2006-03-24 | 2009-06-03 | 诺华疫苗和诊断有限两合公司 | 无需冷藏储存流感疫苗 |
ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
EP1902727A1 (de) * | 2006-09-22 | 2008-03-26 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
WO2008031878A1 (en) * | 2006-09-15 | 2008-03-20 | Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH | A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases |
WO2009001217A2 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
EP3272359A1 (en) * | 2010-07-23 | 2018-01-24 | Novavax AB | Influenza vaccine |
EP2618838A1 (en) | 2010-09-20 | 2013-07-31 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
CN103857403B (zh) | 2011-10-03 | 2019-04-12 | Mx佐剂股份公司 | 纳米颗粒、制备方法以及其应用 |
JP6294828B2 (ja) | 2011-11-28 | 2018-03-14 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | インフルエンザウイルスワクチンおよびその使用 |
SG11201405228VA (en) | 2012-03-12 | 2014-11-27 | Crucell Holland Bv | Batches of recombinant adenovirus with altered terminal ends |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
SG11201405803PA (en) | 2012-03-22 | 2014-11-27 | Crucell Holland Bv | Vaccine against rsv |
JP6494527B2 (ja) | 2013-02-07 | 2019-04-03 | ザ チルドレンズ メディカル センター コーポレーション | 肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原 |
AP2015008702A0 (en) | 2013-03-08 | 2015-09-30 | Crucell Holland Bv | Acellular pertussis vaccine |
US9907846B2 (en) | 2013-04-01 | 2018-03-06 | Mx Adjuvac Ab | Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions |
RS58436B1 (sr) | 2013-04-25 | 2019-04-30 | Janssen Vaccines & Prevention Bv | Stabilizovani rastvorljivi pre-fuzioni rsv f polipeptidi |
JP6643981B2 (ja) | 2013-05-30 | 2020-02-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | インフルエンザウイルスワクチンおよびその使用 |
KR102313153B1 (ko) | 2013-06-17 | 2021-10-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 가용성 예비융합 rsv f 폴리펩타이드 |
US10806779B2 (en) | 2013-07-02 | 2020-10-20 | Janssen Vaccines & Prevention B.V. | Method for preparing virosomes |
WO2015000832A1 (en) | 2013-07-02 | 2015-01-08 | Crucell Holland B.V. | Method for preparing virosomes |
KR101821712B1 (ko) | 2013-08-22 | 2018-01-24 | 주식회사 아데나 | 삼칠근 추출물, 비누풀잎 추출물, 검정콩 잎 추출물, 녹두 잎 추출물 및 호랑이콩 잎 추출물을 포함하는 Th2-매개 면역 질환 개선, 예방 또는 치료용 조성물 |
JP6735269B2 (ja) | 2014-07-10 | 2020-08-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | インフルエンザウイルスワクチンおよびその使用 |
PT3215187T (pt) | 2014-11-04 | 2018-11-27 | Janssen Vaccines & Prevention Bv | Vacinas terapêuticas contra hpv16 |
PL3283634T3 (pl) | 2015-04-14 | 2019-10-31 | Janssen Vaccines & Prevention Bv | Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem |
PL3319633T3 (pl) | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Szczepionka przeciwko rsv |
JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された可溶性融合前rsv fポリペプチド |
MY195389A (en) | 2015-08-20 | 2023-01-18 | Janssen Vaccines & Prevention Bv | Therapeutic HPV18 Vaccines |
US10538557B2 (en) | 2015-09-02 | 2020-01-21 | Janssen Vaccines & Prevention B.V. | Stabilized viral class I fusion proteins |
AU2016315478B2 (en) | 2015-09-03 | 2023-07-13 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
CN108738312A (zh) | 2015-12-23 | 2018-11-02 | 辉瑞公司 | Rsv f蛋白突变体 |
LT3439672T (lt) | 2016-04-05 | 2021-01-25 | Janssen Vaccines & Prevention B.V. | Stabilizuotas tirpus rsv f baltymas prieš suliejimą, skirtas naudoti rsv infekcijos profilaktikai |
AU2017248018A1 (en) | 2016-04-05 | 2018-09-27 | Janssen Vaccines & Prevention B.V. | Vaccine against RSV |
WO2017192418A1 (en) | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
EP3455358B1 (en) | 2016-05-12 | 2020-08-26 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
MY194419A (en) | 2016-05-30 | 2022-11-30 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
BR112018075969A2 (pt) | 2016-06-20 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | promotor bidirecional potente e equilibrado |
US10744196B2 (en) | 2016-07-14 | 2020-08-18 | Janssen Vaccines & Prevention B.V. | HPV vaccines |
EP3580340A1 (en) | 2017-02-09 | 2019-12-18 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
KR20200053518A (ko) | 2017-09-15 | 2020-05-18 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 면역의 안전한 유도를 위한 방법 |
SI3743106T1 (sl) | 2018-01-23 | 2022-10-28 | Janssen Vaccines & Prevention B. V. | Cepiva proti virusu influence in njihove uporabe |
EP3768308A4 (en) | 2018-03-19 | 2022-01-26 | Novavax, Inc. | MULTIVALENT NANOPARTICLE-BASED FLU VACCINES |
GB201807303D0 (en) | 2018-05-03 | 2018-06-20 | London School Of Hygeine & Tropical Medicine | Glyconjugate vaccines |
MX2020012418A (es) | 2018-05-23 | 2021-04-28 | Adc Therapeutics Sa | Adyuvante molecular. |
KR20210091749A (ko) | 2018-11-13 | 2021-07-22 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합전 rsv f 단백질 |
AU2020263900A1 (en) | 2019-04-25 | 2021-10-14 | Janssen Vaccines & Prevention B.V. | Recombinant influenza antigens |
US20220273787A1 (en) | 2019-05-15 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
KR20220008816A (ko) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료 |
EP4025247A1 (en) | 2019-09-05 | 2022-07-13 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
BR112022014808A2 (pt) | 2020-01-31 | 2022-09-20 | Beth Israel Deaconess Medical Ct Inc | Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2 |
JP2023525785A (ja) | 2020-05-11 | 2023-06-19 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 安定化コロナウイルススパイクタンパク質をコードするrnaレプリコン |
BR112022022859A2 (pt) | 2020-05-11 | 2022-12-20 | Janssen Pharmaceuticals Inc | Vacinas contra sars-cov-2 |
BR112022022937A2 (pt) | 2020-05-11 | 2022-12-20 | Janssen Pharmaceuticals Inc | Proteínas de fusão estabilizadas de proteína de pico de coronavírus |
US20230233661A1 (en) | 2020-06-29 | 2023-07-27 | Janssen Vaccines & Prevention B.V. | Vaccine combination against repiratory syncytial virus infection |
EP4175971A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
JP2024509756A (ja) | 2021-02-19 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前rsv fb抗原 |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
WO2023110618A1 (en) | 2021-12-16 | 2023-06-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
WO2023217988A1 (en) | 2022-05-12 | 2023-11-16 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
WO2024017682A1 (en) | 2022-07-18 | 2024-01-25 | Janssen Vaccines & Prevention B.V. | Rsv immunogens |
US20240042021A1 (en) | 2022-08-01 | 2024-02-08 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
WO2024061753A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized trimeric class i fusion proteins |
WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
WO2024074584A1 (en) | 2022-10-06 | 2024-04-11 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion piv3 f proteins |
WO2024104947A2 (en) | 2022-11-14 | 2024-05-23 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
DK166762B1 (da) * | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
SE0301998D0 (sv) * | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
-
2002
- 2002-07-05 SE SE0202110A patent/SE0202110D0/xx unknown
-
2003
- 2003-07-07 BR BRPI0312472A patent/BRPI0312472B8/pt active IP Right Grant
- 2003-07-07 US US10/520,022 patent/US20060121065A1/en not_active Abandoned
- 2003-07-07 NZ NZ537661A patent/NZ537661A/en not_active IP Right Cessation
- 2003-07-07 EP EP03738849A patent/EP1539231B1/en not_active Expired - Lifetime
- 2003-07-07 JP JP2004519469A patent/JP4636877B2/ja not_active Expired - Lifetime
- 2003-07-07 WO PCT/SE2003/001180 patent/WO2004004762A1/en active Application Filing
- 2003-07-07 CA CA2491457A patent/CA2491457C/en not_active Expired - Lifetime
- 2003-07-07 ES ES03738849T patent/ES2328474T3/es not_active Expired - Lifetime
- 2003-07-07 DK DK03738849T patent/DK1539231T3/da active
- 2003-07-07 AT AT03738849T patent/ATE434443T1/de active
- 2003-07-07 DE DE60328108T patent/DE60328108D1/de not_active Expired - Lifetime
- 2003-07-07 AU AU2003245220A patent/AU2003245220B2/en not_active Expired
-
2005
- 2005-01-04 ZA ZA200500073A patent/ZA200500073B/xx unknown
-
2014
- 2014-12-31 US US14/587,116 patent/US10729764B2/en active Active
-
2020
- 2020-03-19 US US16/823,836 patent/US20200215189A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060121065A1 (en) | 2006-06-08 |
JP2006511451A (ja) | 2006-04-06 |
ES2328474T3 (es) | 2009-11-13 |
JP4636877B2 (ja) | 2011-02-23 |
US20200215189A1 (en) | 2020-07-09 |
ATE434443T1 (de) | 2009-07-15 |
SE0202110D0 (sv) | 2002-07-05 |
BR0312472A (pt) | 2005-04-26 |
WO2004004762A1 (en) | 2004-01-15 |
BRPI0312472B8 (pt) | 2021-05-25 |
EP1539231A1 (en) | 2005-06-15 |
US20150209425A1 (en) | 2015-07-30 |
CA2491457C (en) | 2012-09-04 |
DE60328108D1 (de) | 2009-08-06 |
EP1539231B1 (en) | 2009-06-24 |
AU2003245220B2 (en) | 2009-04-23 |
US10729764B2 (en) | 2020-08-04 |
NZ537661A (en) | 2008-08-29 |
AU2003245220A1 (en) | 2004-01-23 |
BRPI0312472B1 (pt) | 2019-07-16 |
ZA200500073B (en) | 2006-02-22 |
CA2491457A1 (en) | 2004-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1539231T3 (da) | Iscom-præparation og anvendelse deraf | |
NZ512011A (en) | Improved saponin adjuvant compositions and methods relating thereto | |
CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
MY129263A (en) | Vaccine composition | |
NO20031646L (no) | Adjuvanssammensetning omfattende et immunostimulatorisk oligonukleotid og en tokol | |
MA29406B1 (fr) | Vaccin toxoide alpha de c. perfringens | |
NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
NO20074392L (no) | Vaksine | |
WO2006113909A3 (en) | Humanized anti-cd70 binding agents and uses thereof | |
NO20071609L (no) | Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker | |
MXPA04001224A (es) | Agentes para incrementar la respuesta inmune. | |
DK1089968T3 (da) | Thyroideahormonanaloger og fremgangsmåder til deres fremstilling | |
BR0211761A (pt) | depsipeptìdeos e processos para preparar os mesmos | |
ATE389397T1 (de) | Adjuvante zusammensetzungen | |
BRPI0308606B8 (pt) | compostos derivados de hemiasterlina e composição farmacêutica compreendendo os mesmos | |
BR0207528A (pt) | Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo | |
AU2002310474A1 (en) | Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same | |
DK1487859T3 (da) | Fremstillingsmetoder til at fremstille Eplerenon | |
WO2021158755A3 (en) | Leptospiral proteins and uses thereof | |
WO2002082091A3 (en) | Method for identification of proteins from intracellular bacteria | |
MX2021013391A (es) | Conjugado de anticuerpo anti-bcma, composiciones que comprenden el mismo, y metodos de fabricacion y uso del mismo. | |
WO2007031334A3 (en) | Vaccines comprising truncated hbc core protein plus saponin-based adjuvants | |
WO2023235660A3 (en) | Flavivirus immunogens and vaccine compositions and methods of using the same |